Abstract 2904: CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice

While chimeric antigen receptor (CAR)-engineered immune cell therapies have been at the forefront of cancer immunotherapy for hematological malignancies, patients with solid tumors have yet to benefit from such therapies. Engineered, off-the-shelf, allogeneic natural killer (NK) cells are particular...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2023-04, Vol.83 (7_Supplement), p.2904-2904
Main Authors: Hamza, Bashar, Nunez, Angela, Marques, Marilyn, Barandiaran, Alexia, Moreno, Henry, Moore, Finola, Walsh, Meghan, Choi, Eugene, Pradhan, Kisha, Daniel, Krista, Johnson, Jennifer, Franco, Charlotte, Alvarez, Andres, Malakian, Karl, Wong, Keith H., Gold, Joseph, Suri, Vipin, Picarella, Dominic
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c984-f70675c85da874495cc2043a9411ca6bb30f89b7eb1cfc911a5ff0b14d1693343
cites
container_end_page 2904
container_issue 7_Supplement
container_start_page 2904
container_title Cancer research (Chicago, Ill.)
container_volume 83
creator Hamza, Bashar
Nunez, Angela
Marques, Marilyn
Barandiaran, Alexia
Moreno, Henry
Moore, Finola
Walsh, Meghan
Choi, Eugene
Pradhan, Kisha
Daniel, Krista
Johnson, Jennifer
Franco, Charlotte
Alvarez, Andres
Malakian, Karl
Wong, Keith H.
Gold, Joseph
Suri, Vipin
Picarella, Dominic
description While chimeric antigen receptor (CAR)-engineered immune cell therapies have been at the forefront of cancer immunotherapy for hematological malignancies, patients with solid tumors have yet to benefit from such therapies. Engineered, off-the-shelf, allogeneic natural killer (NK) cells are particularly attractive as cell therapies for solid tumors given their clinical safety, efficacy, and multimodal recognition of tumor cells. We describe here the pre-clinical pharmacokinetics, efficacy, biodistribution and safety of CAT-179, a novel allogeneic, cryopreserved CAR-NK cell therapy, in naïve animals as well as multiple xenograft models of HER2-amplified ovarian and gastric cancer. CAT-179 cells are engineered to express an optimized HER2-directed CAR to effectively target tumor cells, a transforming growth factor b (TGFβ) dominant negative receptor (DNR) to protect against TGFβ-mediated immunosuppression, and interleukin-15 (IL-15) to enhance NK cell persistence. A single intravenous (IV) dose of CAT-179 resulted in IL-15-dependent (p
doi_str_mv 10.1158/1538-7445.AM2023-2904
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1538_7445_AM2023_2904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1158_1538_7445_AM2023_2904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c984-f70675c85da874495cc2043a9411ca6bb30f89b7eb1cfc911a5ff0b14d1693343</originalsourceid><addsrcrecordid>eNpNkO1KwzAUhoMoOKeXIJwLWGbSNGvjv1L2hVNh9H9J06RU-kXSyXZZeiFeky0T2a9zeDnvA-dB6JGSOaU8fKKchTjwfT6PXj3iMewJ4l-hyX9-fbHfojvnPgghnBI-QV9R5norVQ9j6RniKME0EDOQDciqagvd6FLB2wsoXVXQ2TY_DMf62FntXNkUsFnuPRxH-xlsd5jyoZhDsl79fEPe1mUjmx4aXci-_NRgtdJd39oZ5Acrs-o0JMUI0u7MueAeddMWVpoe-kPdWgdlA3Wp9D26MbJy-uFvTlGyWibxBu_e19s42mElQh-bgCwCrkKey3B4W3ClPOIzKXxKlVxkGSMmFFmgM6qMEpRKbgzJqJ_ThWDMZ1PEz1hlW-esNmlny1raU0pJOmpPR6XpqDQ9a09Hg-wXFZ516Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 2904: CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice</title><source>EZB Electronic Journals Library</source><creator>Hamza, Bashar ; Nunez, Angela ; Marques, Marilyn ; Barandiaran, Alexia ; Moreno, Henry ; Moore, Finola ; Walsh, Meghan ; Choi, Eugene ; Pradhan, Kisha ; Daniel, Krista ; Johnson, Jennifer ; Franco, Charlotte ; Alvarez, Andres ; Malakian, Karl ; Wong, Keith H. ; Gold, Joseph ; Suri, Vipin ; Picarella, Dominic</creator><creatorcontrib>Hamza, Bashar ; Nunez, Angela ; Marques, Marilyn ; Barandiaran, Alexia ; Moreno, Henry ; Moore, Finola ; Walsh, Meghan ; Choi, Eugene ; Pradhan, Kisha ; Daniel, Krista ; Johnson, Jennifer ; Franco, Charlotte ; Alvarez, Andres ; Malakian, Karl ; Wong, Keith H. ; Gold, Joseph ; Suri, Vipin ; Picarella, Dominic</creatorcontrib><description>While chimeric antigen receptor (CAR)-engineered immune cell therapies have been at the forefront of cancer immunotherapy for hematological malignancies, patients with solid tumors have yet to benefit from such therapies. Engineered, off-the-shelf, allogeneic natural killer (NK) cells are particularly attractive as cell therapies for solid tumors given their clinical safety, efficacy, and multimodal recognition of tumor cells. We describe here the pre-clinical pharmacokinetics, efficacy, biodistribution and safety of CAT-179, a novel allogeneic, cryopreserved CAR-NK cell therapy, in naïve animals as well as multiple xenograft models of HER2-amplified ovarian and gastric cancer. CAT-179 cells are engineered to express an optimized HER2-directed CAR to effectively target tumor cells, a transforming growth factor b (TGFβ) dominant negative receptor (DNR) to protect against TGFβ-mediated immunosuppression, and interleukin-15 (IL-15) to enhance NK cell persistence. A single intravenous (IV) dose of CAT-179 resulted in IL-15-dependent (p&lt;0.0001) expansion and persistence of CAT-179 cells for at least 140 days in NOD-scid IL2Rgnull (NSG) mice, peaking at approximately 15,000 cells/µL of blood (by day 60). Persisting CAT-179 NK cell levels at day 60 were functionally active and significantly reduced tumor burden when challenged intraperitoneally (IP) with HER2+ SKOV3-luc tumor cells. No significant changes in body weight or condition were observed during this study. The therapeutic anti-tumor activity of CAT-179 against established tumors was assayed using two different xenograft models. In the first model, NSG mice were given an IP dose of 1 million SKOV3-luc tumor cells (derived from ovarian cancer) followed by either 4 million CAT-179 or control NK cells on days 4, 11 and 18. CAT-179 dosed animals showed a rapid and sustained 95% decline in tumor burden (p&lt;0.0001) and a significant extension in survival relative to animals dosed with control NK cells (p&lt;0.0001). In the second model, 1 million HER2+ N87 cancer cells (derived from gastric cancer) were implanted subcutaneously into the right flank of NSG mice. When tumors reached 70mm3, a single IV dose of 2M CAT-179 or control NK cells was administered. CAT-179 dosed animals showed a 96% durable tumor regression and significant survival benefit relative to animals dosed with control NK cells (p&lt;0.0001). Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15. Citation Format: Bashar Hamza, Angela Nunez, Marilyn Marques, Alexia Barandiaran, Henry Moreno, Finola Moore, Meghan Walsh, Eugene Choi, Kisha Pradhan, Krista Daniel, Jennifer Johnson, Charlotte Franco, Andres Alvarez, Karl Malakian, Keith H. Wong, Joseph Gold, Vipin Suri, Dominic Picarella. CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2904.</description><identifier>ISSN: 1538-7445</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2023-2904</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2904-2904</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c984-f70675c85da874495cc2043a9411ca6bb30f89b7eb1cfc911a5ff0b14d1693343</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Hamza, Bashar</creatorcontrib><creatorcontrib>Nunez, Angela</creatorcontrib><creatorcontrib>Marques, Marilyn</creatorcontrib><creatorcontrib>Barandiaran, Alexia</creatorcontrib><creatorcontrib>Moreno, Henry</creatorcontrib><creatorcontrib>Moore, Finola</creatorcontrib><creatorcontrib>Walsh, Meghan</creatorcontrib><creatorcontrib>Choi, Eugene</creatorcontrib><creatorcontrib>Pradhan, Kisha</creatorcontrib><creatorcontrib>Daniel, Krista</creatorcontrib><creatorcontrib>Johnson, Jennifer</creatorcontrib><creatorcontrib>Franco, Charlotte</creatorcontrib><creatorcontrib>Alvarez, Andres</creatorcontrib><creatorcontrib>Malakian, Karl</creatorcontrib><creatorcontrib>Wong, Keith H.</creatorcontrib><creatorcontrib>Gold, Joseph</creatorcontrib><creatorcontrib>Suri, Vipin</creatorcontrib><creatorcontrib>Picarella, Dominic</creatorcontrib><title>Abstract 2904: CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice</title><title>Cancer research (Chicago, Ill.)</title><description>While chimeric antigen receptor (CAR)-engineered immune cell therapies have been at the forefront of cancer immunotherapy for hematological malignancies, patients with solid tumors have yet to benefit from such therapies. Engineered, off-the-shelf, allogeneic natural killer (NK) cells are particularly attractive as cell therapies for solid tumors given their clinical safety, efficacy, and multimodal recognition of tumor cells. We describe here the pre-clinical pharmacokinetics, efficacy, biodistribution and safety of CAT-179, a novel allogeneic, cryopreserved CAR-NK cell therapy, in naïve animals as well as multiple xenograft models of HER2-amplified ovarian and gastric cancer. CAT-179 cells are engineered to express an optimized HER2-directed CAR to effectively target tumor cells, a transforming growth factor b (TGFβ) dominant negative receptor (DNR) to protect against TGFβ-mediated immunosuppression, and interleukin-15 (IL-15) to enhance NK cell persistence. A single intravenous (IV) dose of CAT-179 resulted in IL-15-dependent (p&lt;0.0001) expansion and persistence of CAT-179 cells for at least 140 days in NOD-scid IL2Rgnull (NSG) mice, peaking at approximately 15,000 cells/µL of blood (by day 60). Persisting CAT-179 NK cell levels at day 60 were functionally active and significantly reduced tumor burden when challenged intraperitoneally (IP) with HER2+ SKOV3-luc tumor cells. No significant changes in body weight or condition were observed during this study. The therapeutic anti-tumor activity of CAT-179 against established tumors was assayed using two different xenograft models. In the first model, NSG mice were given an IP dose of 1 million SKOV3-luc tumor cells (derived from ovarian cancer) followed by either 4 million CAT-179 or control NK cells on days 4, 11 and 18. CAT-179 dosed animals showed a rapid and sustained 95% decline in tumor burden (p&lt;0.0001) and a significant extension in survival relative to animals dosed with control NK cells (p&lt;0.0001). In the second model, 1 million HER2+ N87 cancer cells (derived from gastric cancer) were implanted subcutaneously into the right flank of NSG mice. When tumors reached 70mm3, a single IV dose of 2M CAT-179 or control NK cells was administered. CAT-179 dosed animals showed a 96% durable tumor regression and significant survival benefit relative to animals dosed with control NK cells (p&lt;0.0001). Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15. Citation Format: Bashar Hamza, Angela Nunez, Marilyn Marques, Alexia Barandiaran, Henry Moreno, Finola Moore, Meghan Walsh, Eugene Choi, Kisha Pradhan, Krista Daniel, Jennifer Johnson, Charlotte Franco, Andres Alvarez, Karl Malakian, Keith H. Wong, Joseph Gold, Vipin Suri, Dominic Picarella. CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2904.</description><issn>1538-7445</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpNkO1KwzAUhoMoOKeXIJwLWGbSNGvjv1L2hVNh9H9J06RU-kXSyXZZeiFeky0T2a9zeDnvA-dB6JGSOaU8fKKchTjwfT6PXj3iMewJ4l-hyX9-fbHfojvnPgghnBI-QV9R5norVQ9j6RniKME0EDOQDciqagvd6FLB2wsoXVXQ2TY_DMf62FntXNkUsFnuPRxH-xlsd5jyoZhDsl79fEPe1mUjmx4aXci-_NRgtdJd39oZ5Acrs-o0JMUI0u7MueAeddMWVpoe-kPdWgdlA3Wp9D26MbJy-uFvTlGyWibxBu_e19s42mElQh-bgCwCrkKey3B4W3ClPOIzKXxKlVxkGSMmFFmgM6qMEpRKbgzJqJ_ThWDMZ1PEz1hlW-esNmlny1raU0pJOmpPR6XpqDQ9a09Hg-wXFZ516Q</recordid><startdate>20230404</startdate><enddate>20230404</enddate><creator>Hamza, Bashar</creator><creator>Nunez, Angela</creator><creator>Marques, Marilyn</creator><creator>Barandiaran, Alexia</creator><creator>Moreno, Henry</creator><creator>Moore, Finola</creator><creator>Walsh, Meghan</creator><creator>Choi, Eugene</creator><creator>Pradhan, Kisha</creator><creator>Daniel, Krista</creator><creator>Johnson, Jennifer</creator><creator>Franco, Charlotte</creator><creator>Alvarez, Andres</creator><creator>Malakian, Karl</creator><creator>Wong, Keith H.</creator><creator>Gold, Joseph</creator><creator>Suri, Vipin</creator><creator>Picarella, Dominic</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230404</creationdate><title>Abstract 2904: CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice</title><author>Hamza, Bashar ; Nunez, Angela ; Marques, Marilyn ; Barandiaran, Alexia ; Moreno, Henry ; Moore, Finola ; Walsh, Meghan ; Choi, Eugene ; Pradhan, Kisha ; Daniel, Krista ; Johnson, Jennifer ; Franco, Charlotte ; Alvarez, Andres ; Malakian, Karl ; Wong, Keith H. ; Gold, Joseph ; Suri, Vipin ; Picarella, Dominic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c984-f70675c85da874495cc2043a9411ca6bb30f89b7eb1cfc911a5ff0b14d1693343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamza, Bashar</creatorcontrib><creatorcontrib>Nunez, Angela</creatorcontrib><creatorcontrib>Marques, Marilyn</creatorcontrib><creatorcontrib>Barandiaran, Alexia</creatorcontrib><creatorcontrib>Moreno, Henry</creatorcontrib><creatorcontrib>Moore, Finola</creatorcontrib><creatorcontrib>Walsh, Meghan</creatorcontrib><creatorcontrib>Choi, Eugene</creatorcontrib><creatorcontrib>Pradhan, Kisha</creatorcontrib><creatorcontrib>Daniel, Krista</creatorcontrib><creatorcontrib>Johnson, Jennifer</creatorcontrib><creatorcontrib>Franco, Charlotte</creatorcontrib><creatorcontrib>Alvarez, Andres</creatorcontrib><creatorcontrib>Malakian, Karl</creatorcontrib><creatorcontrib>Wong, Keith H.</creatorcontrib><creatorcontrib>Gold, Joseph</creatorcontrib><creatorcontrib>Suri, Vipin</creatorcontrib><creatorcontrib>Picarella, Dominic</creatorcontrib><collection>CrossRef</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamza, Bashar</au><au>Nunez, Angela</au><au>Marques, Marilyn</au><au>Barandiaran, Alexia</au><au>Moreno, Henry</au><au>Moore, Finola</au><au>Walsh, Meghan</au><au>Choi, Eugene</au><au>Pradhan, Kisha</au><au>Daniel, Krista</au><au>Johnson, Jennifer</au><au>Franco, Charlotte</au><au>Alvarez, Andres</au><au>Malakian, Karl</au><au>Wong, Keith H.</au><au>Gold, Joseph</au><au>Suri, Vipin</au><au>Picarella, Dominic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 2904: CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2023-04-04</date><risdate>2023</risdate><volume>83</volume><issue>7_Supplement</issue><spage>2904</spage><epage>2904</epage><pages>2904-2904</pages><issn>1538-7445</issn><eissn>1538-7445</eissn><abstract>While chimeric antigen receptor (CAR)-engineered immune cell therapies have been at the forefront of cancer immunotherapy for hematological malignancies, patients with solid tumors have yet to benefit from such therapies. Engineered, off-the-shelf, allogeneic natural killer (NK) cells are particularly attractive as cell therapies for solid tumors given their clinical safety, efficacy, and multimodal recognition of tumor cells. We describe here the pre-clinical pharmacokinetics, efficacy, biodistribution and safety of CAT-179, a novel allogeneic, cryopreserved CAR-NK cell therapy, in naïve animals as well as multiple xenograft models of HER2-amplified ovarian and gastric cancer. CAT-179 cells are engineered to express an optimized HER2-directed CAR to effectively target tumor cells, a transforming growth factor b (TGFβ) dominant negative receptor (DNR) to protect against TGFβ-mediated immunosuppression, and interleukin-15 (IL-15) to enhance NK cell persistence. A single intravenous (IV) dose of CAT-179 resulted in IL-15-dependent (p&lt;0.0001) expansion and persistence of CAT-179 cells for at least 140 days in NOD-scid IL2Rgnull (NSG) mice, peaking at approximately 15,000 cells/µL of blood (by day 60). Persisting CAT-179 NK cell levels at day 60 were functionally active and significantly reduced tumor burden when challenged intraperitoneally (IP) with HER2+ SKOV3-luc tumor cells. No significant changes in body weight or condition were observed during this study. The therapeutic anti-tumor activity of CAT-179 against established tumors was assayed using two different xenograft models. In the first model, NSG mice were given an IP dose of 1 million SKOV3-luc tumor cells (derived from ovarian cancer) followed by either 4 million CAT-179 or control NK cells on days 4, 11 and 18. CAT-179 dosed animals showed a rapid and sustained 95% decline in tumor burden (p&lt;0.0001) and a significant extension in survival relative to animals dosed with control NK cells (p&lt;0.0001). In the second model, 1 million HER2+ N87 cancer cells (derived from gastric cancer) were implanted subcutaneously into the right flank of NSG mice. When tumors reached 70mm3, a single IV dose of 2M CAT-179 or control NK cells was administered. CAT-179 dosed animals showed a 96% durable tumor regression and significant survival benefit relative to animals dosed with control NK cells (p&lt;0.0001). Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15. Citation Format: Bashar Hamza, Angela Nunez, Marilyn Marques, Alexia Barandiaran, Henry Moreno, Finola Moore, Meghan Walsh, Eugene Choi, Kisha Pradhan, Krista Daniel, Jennifer Johnson, Charlotte Franco, Andres Alvarez, Karl Malakian, Keith H. Wong, Joseph Gold, Vipin Suri, Dominic Picarella. CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2904.</abstract><doi>10.1158/1538-7445.AM2023-2904</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1538-7445
ispartof Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2904-2904
issn 1538-7445
1538-7445
language eng
recordid cdi_crossref_primary_10_1158_1538_7445_AM2023_2904
source EZB Electronic Journals Library
title Abstract 2904: CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A54%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%202904:%20CAT-179,%20an%20allogeneic%20NK%20cell%20product%20expressing%20HER2-CAR,%20IL-15%20and%20TGF%CE%B2%20dominant%20negative%20receptor,%20durably%20regresses%20HER2-expressing%20xenograft%20tumors%20in%20mice&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Hamza,%20Bashar&rft.date=2023-04-04&rft.volume=83&rft.issue=7_Supplement&rft.spage=2904&rft.epage=2904&rft.pages=2904-2904&rft.issn=1538-7445&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2023-2904&rft_dat=%3Ccrossref%3E10_1158_1538_7445_AM2023_2904%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c984-f70675c85da874495cc2043a9411ca6bb30f89b7eb1cfc911a5ff0b14d1693343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true